COMMUNIQUÉS West-GlobeNewswire

CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
06/05/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 06, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that AZD5904, a potent inhibitor of human Myeloperoxidase, originally [...]
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
06/05/2026
Landmark data positions ERNA-101 as a potential game-changing immunotherapy and a major catalyst for future clinical and shareholder value CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: [...]
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
06/05/2026
Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology [...]
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
06/05/2026
InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseases Capital Markets Day highlighting the [...]
Cannara Completes Acquisition of Medican Organic Inc.
06/05/2026
MONTREAL, May 06, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, the “ Company ”, “ us ” or “ we ”) ( TSX: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Twentyeight Health Partners with ŌURA to Expand Access to Comprehensive Contraceptive Care
06/05/2026
Facilitating Clinical Treatment for Women by Incorporating Comprehensive Data and Insights from ŌURA NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Twentyeight Health, the leading provider-led digital women’s healthcare [...]
CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference
06/05/2026
ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of America Securities 2026 Global [...]
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
06/05/2026
Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commercialization of novel therapies CHICAGO and FORT WORTH, Texas, May 06, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, [...]
MedWell Ai, Inc Reports Q3 Revenues Of $618,676 And Provides Corporate Update
06/05/2026
CLEARWATER, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- via IBN -- MedWell Ai, Inc, (OTCQB:MWAI) ("Company") is a portfolio company, specializing in AI-driven solutions for B2B markets in pharmaceuticals, healthcare, and [...]
Jito Foundation and Solana Company (NASDAQ: HSDT) Announce Strategic Partnership to Expand Institutional Solana Infrastructure Across Asia-Pacific Region
06/05/2026
Pairing Jito's market layer technology and Solana Company's institutional Pacific Backbone platform intended to advance validator infrastructure and staking solutions across Asia-Pacific MIAMI, May 06, 2026 (GLOBE [...]
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
06/05/2026
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine [...]
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
06/05/2026
ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026 JELMYTO achieved $21.7 million in [...]
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
06/05/2026
MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]
Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101
06/05/2026
Final results confirm and build on interim BIRCH results in 23 ICH patients Primary safety endpoint met with no mortality observed Encouraging efficacy signals on all clinical and biomarker endpoints New adaptive [...]
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors
06/05/2026
Sequence LifeScience TM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “ [...]
Better Blend Continues Growth with Second Lexington Location
06/05/2026
Fast-growing Midwest brand brings low-sugar, high-protein menu to the area LEXINGTON, Ky., May 06, 2026 (GLOBE NEWSWIRE) -- Better Blend, a rapidly growing smoothie and bowl brand, opened its second location in [...]
Brain Cancer Canada Awards $75,000 to Groundbreaking Pediatric Brain Cancer Study at University of Manitoba Targeting Hard-to-Treat DMG-P Tumours
06/05/2026
TORONTO, May 06, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada, the country’s only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide, is proud to award $75,000 to first-of- [...]
SeaStar Medical to Report First Quarter Financial Results on May 13, 2026
06/05/2026
DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
06/05/2026
- The approval of Beyonttra in Brazil is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date, including: - [...]

Pages